Although several phase II/III randomized clinical trials have been conducted to assess the efficacy and toxicity of anti-PD-1/PD-L1 antibodies for previously treated patients with advanced NSCLC, outcomes such as progression-free survival (PFS) seem to be controversial. The gene discussed is CD274; the disease is non-small cell lung carcinoma.